Saxony Capital Management LLC Raises Position in Johnson & Johnson (NYSE:JNJ)

Saxony Capital Management LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,885 shares of the company’s stock after purchasing an additional 130 shares during the period. Saxony Capital Management LLC’s holdings in Johnson & Johnson were worth $298,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Norges Bank purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $4,071,642,000. Wellington Management Group LLP raised its holdings in shares of Johnson & Johnson by 16.4% in the fourth quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock worth $3,764,852,000 after buying an additional 3,391,657 shares during the period. International Assets Investment Management LLC raised its holdings in shares of Johnson & Johnson by 7,875.8% in the fourth quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock worth $327,647,000 after buying an additional 2,064,175 shares during the period. Janney Montgomery Scott LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $193,050,000. Finally, Focused Investors Fund L P purchased a new position in Johnson & Johnson during the 1st quarter worth $193,996,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday. The Goldman Sachs Group initiated coverage on Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price on the stock. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Monday, June 17th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 30th. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $174.07.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded up $0.33 on Friday, hitting $146.02. The company’s stock had a trading volume of 2,817,683 shares, compared to its average volume of 7,317,314. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm has a fifty day moving average price of $147.94 and a 200-day moving average price of $153.79. The company has a market capitalization of $351.42 billion, a price-to-earnings ratio of 9.03, a price-to-earnings-growth ratio of 2.42 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same period in the previous year, the firm posted $2.68 EPS. Johnson & Johnson’s revenue was up 2.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.40%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.